目的 分析咸陽市中心醫(yī)院吸入制劑應用情況，為患者及臨床使用提供參考。方法 對2018—2020年咸陽市中心醫(yī)院肺部吸入制劑的種類、銷售額、用藥頻度（DDDs）、日均費用（DDC）和藥品使用排序比（B/A）進行統(tǒng)計分析。結果 2018—2020年咸陽市中心醫(yī)院肺部吸入制劑的用藥金額呈逐年上升趨勢，總金額的構成比基本保持穩(wěn)定。其中總金額排前3位的制劑分別為吸入用布地奈德混懸液、布地奈德福莫特羅粉吸入劑、吸入用復方異丙托溴銨；DDDs排名前3位的制劑分別是布地奈德福莫特羅粉吸入劑、吸入用布地奈德混懸液、噻托溴銨粉吸入劑；DDC排名前3位的制劑分別是吸入用復方異丙托溴銨溶液、吸入用布地奈德混懸液、布地奈德福莫特羅粉吸入劑；B/A值均低于2。結論 2018—2020年度咸陽市中心醫(yī)院肺部吸入制劑使用及價格結構較為合理。

Objective To investigate the application of pulmonary inhalers in Xianyang Central Hospital,and to provide reference for rational drug use in clinic. Methods The utilization of pulmonary inhalers in Xianyang Central Hospital from 2018 to 2020 was analyzed statistically in respects of drug types, consumption sum, DDDs, DDC, rank ratios of total consumption, and B/A. Results Consumption sum of pulmonary inhalers had a rising trend from 2018 to 2020, but the proportions of pulmonary inhaler in the total drug use were kept stable. The top 3 drug of consumption sum were Budesonide Suspension for inhalation, Budesonide and Formoterol Fumarate Powder for inhalation, and Compound Ipratropium Bromide Solution for inhalation. The top 3 drugs of DDDs were Budesonide and Formoterol Fumarate Powder for inhalation, Budesonide Suspension for inhalation, and Tiotropium Bromide Powder for inhalation. The top 3 drugs of DDC were Compound Ipratropium Bromide Solution for inhalation, Budesonide Suspension for inhalation, and Budesonide and Formoterol Fumarate Powder for inhalation. B/A of specific pulmonary inhalers were low to 2.00. Conclusion The overall drug use and the price structures in Xianyang Central Hospital from 2018 to 2020 are reasonable.

R974